TP53 and breast carcinoma: Treatment of several breast cancer cell lines (MCF7, MDA-MB-231, and ZR-75-1) with TF1 produced a dose-dependent reduction in cell viability with a greater effect observed in MCF-7 cells which express wildtype p53 and a lesser effect in p53-mutant MDA-MB-231 cells (Table 1) [18].